Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 2/20 | 0.33 |
| ▸ | KLK1 | P06870 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29314651 | 0.91 | NAMPT (0.36) | TLR8TLR7SCN9ANAMPTMAP4K4 | |
| SCHEMBL29314663 | 0.91 | KDR (0.34) | KLKB1KLK1TLR8TLR7NAMPT | |
| SCHEMBL29320279 | 0.89 | KDM4E (0.38) | TLR8TLR7 | |
| SCHEMBL29314696 | 0.88 | BACE1 (0.38) | MAPT | |
| SCHEMBL29314643 | 0.88 | TLR8 (0.34) | KLKB1TLR8TLR7NAMPTMAPT | |
| SCHEMBL29314683 | 0.87 | ADORA3 (0.35) | TLR8TLR7NAMPTMAP4K4MAPT | |
| SCHEMBL29314717 | 0.87 | ADORA3 (0.35) | TLR8TLR7NAMPTMAP4K4 | |
| SCHEMBL29320672 | 0.86 | TLR8 (0.37) | KLKB1TLR8TLR7NAMPTMAP4K4 | |
| SCHEMBL29320666 | 0.86 | TLR8 (0.33) | TLR8TLR7NAMPT | |
| SCHEMBL29314704 | 0.86 | NAMPT (0.35) | KLKB1TLR8TLR7NAMPTMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | KLKB1 508/4885KLK1 845/4885TLR8 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.